Cardiovascular
The circulatory system is a vast network of organs and vessels that is responsible for the flow of blood, nutrients, oxygen and other gases, and hormones to and from cells. The system consists of three independent systems that work together: the heart (cardiovascular), lungs (pulmonary), and arteries, veins, coronary and portal vessels (systemic). Together, the heart, blood, and blood vessels make up the cardiovascular component of the circulatory system. It includes the pulmonary circulation, a "loop" through the lungs where blood is oxygenated. It also incorporates the systemic circulation, which runs through the rest of the body to provide oxygenated blood.
Because of its vastness and critical nature, the circulatory system is one of the systems of the body most prone to disease. Disorders of this system are the leading cause of death among adults in the majority of countries world-wide, arteriosclerosis being one of the most common diseases. It is characterized by fatty deposits in the arteries that cause the walls to stiffen and thicken the walls, and may result in restricted blood flow and ischemia. This may result in symptoms such as angina and dyspnea, necrosis, and ultimately in heart attack or stroke. Hypertension, another circulatory is disease, causes the heart to work harder and can lead to complications as a heart attack, a stroke, or kidney failure. Abnormal blood lipid levels, that is high total cholesterol, high levels of triglycerides, high levels of low-density lipoprotein or low levels of high-density lipoprotein (HDL) cholesterol all increase the risk of heart disease and stroke, and are of particular interest of modern research. Besides changing food intake habits of patients suffering from cardiovascular diseases, in combination with the stimulation to increase physical exercise, special medication may also modify a patients blood lipid profile and prevent the person from developing life threatening circulatory diseases.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
3144 | (+)-Blebbistatin | Negative control of (±)-Blebbistatin as an inhibitor of class II myosins | €90.00 | |
3074 | (-)-Blebbistatin | Selective inhibitor of class II myosins; Active enantiomer of (±)-Blebbistatin | €90.00 | |
2830 | (R)-CE3F4 | Potent inhibitor of EPAC1 | €120.00 | |
2718 | (±)-Blebbistatin | Potent and specific inhibitor of class II myosins | €95.00 | |
2989 | 15-LOX-1 inhibitor i472 | Inhibitor of 15-lipoxygenase-1 (15-LOX-1) | €170.00 | |
4229 | 2',5'-Dideoxyadenosine | P-Site inhibitor of adenylate cyclase | Recently added | €90.00 |
2496 | 2,5-Dimethylcelecoxib | Celecoxib analog with anti-tumor properties, lacking COX-2 inhibitory activity | €75.00 | |
1666 | A 357300 hydrochloride | MetAP2 inhibitor | €90.00 | |
2552 | Adjudin | Non-hormonal male contraceptive with anti-proliferative activity | €125.00 | |
4000 | Aficamten | Next-in-class cardiac myosin inhibitor | €160.00 | |
3856 | AHU-377 tris salt | Inhibitor of Neprilysin | Inquire | |
3524 | AKOS-022 | VDAC1 inhibitor | €120.00 | |
2276 | Atglistatin | Potent and selective inhibitor of adipose triglyceride lipase (ATGL) | €90.00 | |
5051 | Axon Ligands™ Cell signaling and Oncology compound library | Axon Ligands™ Cell signaling and Oncology compound library | Inquire | |
2661 | AZD2716 | Potent secreted phospholipase A2 (sPLA2) inhibitor | €145.00 | |
2178 | BCI | Allosteric inhibitor of dual-specificity phosphatases (DUSP) | €75.00 | |
2852 | BCI hydrochloride | Allosteric inhibitor of dual-specificity phosphatases (DUSP) | €75.00 | |
2373 | BEC hydrochloride | Slow-binding pH-dependent inhibitior of Arginase I and II | €120.00 | |
3036 | BI 749327 | Potent, selective and orally bioavailable TRPC6 inhibitor | €160.00 | |
3047 | BI-6C9 | Inhibitor of BID protein | €145.00 | |
2506 | BMS 303141 | Cell-permeable ATP-citrate lyase (ACL) inhibitor | €90.00 | |
2798 | BPKDi | PKD inhibitor | €155.00 | |
2931 | BRD0705 | First-in-class, paralog selective GSK3α inhibitor | €210.00 | |
3153 | BRD5648 | Negative control compound of BRD0705 as a GSK3α inhibitor | €180.00 | |
2662 | CAIX Inhibitor S4 | Carbonic anhydrase (CA) IX/XII inhibitor | €90.00 | |
3574 | Carbazeran | Potent phosphodiesterase inhibitor and an aldehyde oxidase (AO) substrate | €90.00 | |
3738 | CB-1158 dihydrochloride | Orally bioavailable, potent and selective inhibitor of human arginase I | €240.00 | |
3393 | CB096 | Selective RAN inhibitor | €110.00 | |
3570 | CD38 inhibitor compound 78c | Potent, specific, reversible, and uncompetitive inhibitor of CD38 | €140.00 | |
2929 | CE3F4 | Inhibitor of EPAC1 | €95.00 |